Communication Dans Un Congrès Année : 2024

Implementation and validation of a biological dose actor in GATE 10

Résumé

Background: We recently implemented in GATE 10 a biological dose estimator (actor) based on pre- computed cell survival parameter databases to evaluate the biological outcomes (cell survivals, RBE or biological dose) of hadrontherapy treatments. Material and Methods: In this study, we used the new GATE platform (version 10), implementing a biological dose actor based on the modified microkinetic model (mMKM) and the NanOx model. We simulated the MedAustron horizontal beam line equipped with a clinical nozzle enabling proton and carbon ion irradiations with a field size of 20 × 20 cm2 in the clinical available energy ranges from 62 to 252 MeV and 120 to 402 MeV/u. We reproduced proton and carbon ions plans created with the Raystation treatment planning system (TPS) in a liquid water phantom and in a patient. Preliminary results: We provide recommendations to users regarding stepping parameters and pro- duction cuts to ensure enough precision while limiting the computing times. Physical and biological isodoses, cumulative dose volume histograms and relative biological doses received by 95%, 50% and 5% of the tumor volume are calculated with mMKM and NanOx models and compared to Raystation TPS outputs.

Fichier non déposé

Dates et versions

hal-05009136 , version 1 (27-03-2025)

Identifiants

  • HAL Id : hal-05009136 , version 1

Citer

A. Pereda, Thomas Berger, Michaël Beuve, Jean Michel Létang, Etienne Testa, et al.. Implementation and validation of a biological dose actor in GATE 10. The 5th Geant4 International User Conference at the Physics-Medicine-Biology frontier, Mar 2024, Osaka, Japan. ⟨hal-05009136⟩
82 Consultations
0 Téléchargements

Partager

  • More